DAWN
Day One Biopharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$21.53
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 158.2M | 158.2M | 131.2M | — | — |
| Cost of Revenue | 17.2M | 17.2M | 5.3M | — | — |
| Gross Profit | 141.0M | 141.0M | 125.9M | — | — |
| Operating Expenses | |||||
| R&D Expense | 148.1M | 148.1M | 227.7M | 130.5M | 85.6M |
| SG&A Expense | 120.6M | 120.6M | 115.5M | 75.5M | 61.3M |
| General & Admin Expense | 29.3M | — | — | 75.5M | 61.3M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 268.7M | 268.7M | 343.2M | 206.1M | 146.9M |
| Cost and Expenses | 285.9M | 285.9M | 348.4M | 206.1M | 146.9M |
| Operating Income (EBIT) | (127.8M) | (127.8M) | (217.3M) | (206.1M) | (146.9M) |
| Non-Operating | |||||
| Interest Income | 18.5M | 18.5M | 19.7M | 17.2M | 4.7M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 18.5M | 18.5M | 19.7M | 17.2M | 4.7M |
| Other Non-Op Income/Expense | 18.5M | 18.5M | 128.9M | 17.1M | 4.7M |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (109.3M) | (109.3M) | (88.4M) | (188.9M) | (142.2M) |
| Income Tax Expense | (2.0M) | (2.0M) | 7.1M | — | — |
| Bottom Line | |||||
| Net Income | (107.3M) | (107.3M) | (95.5M) | (188.9M) | (142.2M) |
| Earnings from Cont. Ops | (107.3M) | (107.3M) | (95.5M) | (188.9M) | (142.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (107.3M) | (107.3M) | (95.5M) | (188.9M) | (142.2M) |
| Per Share | |||||
| Basic EPS | ($1.04) | ($1.04) | ($1.02) | ($2.37) | ($2.02) |
| Diluted EPS | ($1.04) | ($1.04) | ($1.02) | ($2.37) | ($2.02) |
| Revenue Per Share | $1.53 | $1.53 | $1.40 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 103.4M | 103.4M | 93.6M | 79.8M | 65.5M |
| Diluted Shares Outstanding | 103.4M | 103.4M | 93.6M | 79.8M | 65.5M |
| Profitability Metrics | |||||
| EBITDA | (124.0M) | (124.0M) | (215.2M) | (205.7M) | (146.4M) |
| D&A | 3.8M | 3.8M | 2.0M | 383.0K | 531.0K |
| EBIT | (127.8M) | (127.8M) | (217.3M) | (206.1M) | (146.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Dec 1, 2025